NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Calluna Pharma

Calluna Pharma

Private
OsloHealthcare & Life Scienceshttps://www.callunapharma.com/

Last Round

Series A

Jan 23, 2024

Total Funding Raised

$81.3M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Calluna Pharma is a clinical-stage biotechnology company developing a pipeline of selective antibodies to treat inflammatory and fibrotic diseases by targeting the innate immune system.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

monoclonal antibodybiotechnologydrug discoveryinflammatory diseasefibrotic diseasebiopharmaclinical-stage biotechtherapeutic candidateclinical trialsIPFidiopathic pulmonary fibrosischronic kidney diseaseDAMPsdamage-associated molecular patternsdrug development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Calluna Pharma Comparables

Compare Calluna Pharma with similar companies based on industry and business-model similarity.

Calluna Pharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap

View Full Comparables Set

Access detailed peer comparisons, similarity scores, and market data.

Calluna Pharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJan 23, 2024
View all Funding Rounds

Key People

Founding team and executive leadership

Jonas Hallén

Chief Medical Officer Co-Founder

Founding Team

Mark Gaffney

Chief Executive Officer & Board Member

Executive Team

Calluna Pharma Investors

Notable investors and investment history

Calluna Pharma investors
InvestorRounds
ForbionSeries A
InvestinorSeries A
P53 InvestSeries A
SarsiaSeries A
View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 24, 2026

    Monthly visitors increased 90% MoM.

  • Dec 16, 2025

    Gijs van den Brink appointed as independent director.

View all signals

Calluna Pharma Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Calluna Pharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Calluna Pharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersOslo
Employee Range27
Year Founded2024
Last FundingJan 23, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.